Hamilton Wealth LLC Cuts Stake in Moderna, Inc. $MRNA

Hamilton Wealth LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 23.2% in the first quarter, Holdings Channel reports. The fund owned 80,728 shares of the company’s stock after selling 24,338 shares during the quarter. Hamilton Wealth LLC’s holdings in Moderna were worth $4,101,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in MRNA. MUFG Securities EMEA plc purchased a new stake in Moderna during the second quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new position in shares of Moderna in the fourth quarter worth about $31,000. Canton Hathaway LLC bought a new stake in shares of Moderna in the first quarter valued at approximately $31,000. EverSource Wealth Advisors LLC raised its position in shares of Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after purchasing an additional 801 shares during the period. Finally, Kelleher Financial Advisors purchased a new stake in shares of Moderna during the 4th quarter valued at approximately $39,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several analyst reports. Piper Sandler raised their price objective on shares of Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a report on Friday, June 26th. Bank of America increased their target price on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. The Goldman Sachs Group raised their price target on Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a report on Tuesday, July 21st. Morgan Stanley lifted their price target on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 8th. Finally, Wolfe Research reiterated an “underperform” rating and set a $25.00 price objective on shares of Moderna in a research note on Monday, July 20th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $40.00.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider directly owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 119,406 shares of company stock worth $5,928,762 over the last ninety days. 10.80% of the stock is owned by corporate insiders.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $54.82 on Monday. The firm has a fifty day moving average price of $59.37 and a two-hundred day moving average price of $52.64. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a one year low of $22.28 and a one year high of $85.60. The company has a market cap of $21.75 billion, a price-to-earnings ratio of -6.86 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the prior year, the firm posted ($2.13) earnings per share. The business’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts anticipate that Moderna, Inc. will post -6.41 EPS for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.